HUP9900457A2 - Eljárás, készítmények és kellékkészlet gyógyszerhatóanyagok orális biológiai hasznosulásának a növelésére - Google Patents
Eljárás, készítmények és kellékkészlet gyógyszerhatóanyagok orális biológiai hasznosulásának a növeléséreInfo
- Publication number
- HUP9900457A2 HUP9900457A2 HU9900457A HUP9900457A HUP9900457A2 HU P9900457 A2 HUP9900457 A2 HU P9900457A2 HU 9900457 A HU9900457 A HU 9900457A HU P9900457 A HUP9900457 A HU P9900457A HU P9900457 A2 HUP9900457 A2 HU P9900457A2
- Authority
- HU
- Hungary
- Prior art keywords
- oral administration
- agent
- dihydrocyclosporin
- targeted
- aging
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 230000003712 anti-aging effect Effects 0.000 abstract 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- -1 ketekönazol Chemical compound 0.000 abstract 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 abstract 2
- MQSMWZHHUGSULF-QNGWXLTQSA-N (2s)-n-benzyl-3-(4-chlorophenyl)-n-(1,5-dipyridin-4-ylpentan-3-yl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N(C)[C@@H](CC=2C=CC(Cl)=CC=2)C(=O)N(CC=2C=CC=CC=2)C(CCC=2C=CN=CC=2)CCC=2C=CN=CC=2)=C1 MQSMWZHHUGSULF-QNGWXLTQSA-N 0.000 abstract 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 abstract 1
- TYFOVYYNQGNDKH-HHPJSCBPSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23, Chemical compound CCCC[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-HHPJSCBPSA-N 0.000 abstract 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 1
- 108010036941 Cyclosporins Proteins 0.000 abstract 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 abstract 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 abstract 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- KUSICUWKCBCAHV-ZSINMPTNSA-N [(e,1r,2r)-1-[(2s,5s,11s,14s,17s,20s,23r,26s,29s,32s)-5-ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacont-2-y Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](OC(C)=O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O KUSICUWKCBCAHV-ZSINMPTNSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002576 amiloride Drugs 0.000 abstract 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005260 amiodarone Drugs 0.000 abstract 1
- CGVWPQOFHSAKRR-NDEPHWFRSA-N biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 abstract 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 abstract 1
- 229960004682 cefoperazone Drugs 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- 150000001783 ceramides Chemical class 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 abstract 1
- 229950005878 dexverapamil Drugs 0.000 abstract 1
- 108010040764 dihydrocyclosporin A Proteins 0.000 abstract 1
- 108010040786 dihydrocyclosporin C Proteins 0.000 abstract 1
- 231100000676 disease causative agent Toxicity 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 abstract 1
- 229960003199 etacrynic acid Drugs 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 229940045109 genistein Drugs 0.000 abstract 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 abstract 1
- 235000006539 genistein Nutrition 0.000 abstract 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 abstract 1
- 229960002418 ivermectin Drugs 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 229960001783 nicardipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 abstract 1
- 229960000203 propafenone Drugs 0.000 abstract 1
- 229960001404 quinidine Drugs 0.000 abstract 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 abstract 1
- 229960003147 reserpine Drugs 0.000 abstract 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgya A-tól Z-ig terjedő ciklőspőrinők (Me-Ile-4)-ciklőspőrin, dihidrőciklőspőrin A, dihidrőciklőspőrin C, acetil-ciklőspőrin A, ketőkőnazől, dexverapamil, amiődarőn, nifedipin,rezerpin, kinidin, nikardipin, etakrinsav, prőpafenőn, amilőrid, ergőtalkalőidők, cefőperazőn, tetraciklin, klőrőkin, főszfőmicin,ivermektin, tamőxifen, VX-710, VX-853, genisztein és rőkőnizőflavőnőidők, kalfősztin, ceramidők, mőrfin, mőrfinrőkőnők, egyébőpiőidők vagy őpiőidantagőnisták alkalmazása biőlógiai hasznősűlástfőkőzó szerként farmakőlógiailag hatásős, célzőtt hatóanyag emlősbetegeken végzett őrális adagőlása űtáni biőlógiai hasznősűlásának anövelésére alkalmazható gyógyszer gyártásában. A találmánymegvalósítása lehetővé teszi őlyan gyógyszerek őrális, hatékőnyadagőlását, amelyek eddig csak intravénásan vőltak adagőlhatók őrálisadagőlás űtáni csekély felszívódásűk következtében. A találmányértelmében az új gyógyszeradagőlási főrma külön-külön vagy együttesenegy célzőtt hatóanyag hatásős mennyiségét és a biőlógiai hasznősűlástfőkőzó szert tartalmazza. A főkőzószer őrálisan adagőlható a célzőttgyógyszerhatóanyag adagőlása előtt, azzal együtt vagy azt követően. ŕ
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US707195P | 1995-10-26 | 1995-10-26 | |
| US08/608,776 US5968972A (en) | 1995-10-26 | 1996-02-29 | Method for increasing the oral bioactivity of pharmaceutical agents |
| US08/733,142 US6245805B1 (en) | 1995-10-26 | 1996-10-16 | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9900457A2 true HUP9900457A2 (hu) | 1999-06-28 |
| HUP9900457A3 HUP9900457A3 (en) | 2001-04-28 |
Family
ID=27358262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9900457A HUP9900457A3 (en) | 1995-10-26 | 1996-10-24 | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US6245805B1 (hu) |
| EP (1) | EP0794794B1 (hu) |
| JP (1) | JP3361102B2 (hu) |
| CN (2) | CN1119146C (hu) |
| AT (1) | ATE311903T1 (hu) |
| AU (1) | AU698142B2 (hu) |
| BR (1) | BR9607066A (hu) |
| CA (1) | CA2205534A1 (hu) |
| CZ (1) | CZ202897A3 (hu) |
| DE (2) | DE794794T1 (hu) |
| DK (1) | DK0794794T3 (hu) |
| ES (1) | ES2109899T3 (hu) |
| HK (1) | HK1001960A1 (hu) |
| HU (1) | HUP9900457A3 (hu) |
| IL (1) | IL121160A0 (hu) |
| MX (1) | MX9704629A (hu) |
| NO (1) | NO321091B1 (hu) |
| NZ (1) | NZ324801A (hu) |
| PL (2) | PL188281B1 (hu) |
| RU (1) | RU2217135C2 (hu) |
| SK (1) | SK85997A3 (hu) |
| WO (1) | WO1997015269A2 (hu) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| BR9809694A (pt) * | 1997-05-27 | 2000-10-03 | Baker Norton Pharma | Processo e composição para administração de taxanos oralmente a pacientes humanos |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| AU9785698A (en) | 1997-10-02 | 1999-04-27 | Microcide Pharmaceuticals, Inc. | Fungal efflux pump inhibitors |
| CN100358529C (zh) * | 1998-06-29 | 2008-01-02 | 洛杉矶儿童医院 | 全反式视黄酰胺和神经酰胺降解抑制剂的制药用途 |
| EP1189637B1 (en) | 1999-05-17 | 2006-08-23 | Cancer Research Ventures Limited | Compositions for improving bioavailability of orally administered drugs |
| EP1479382A1 (en) * | 1999-06-18 | 2004-11-24 | IVAX Research, Inc. | Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same |
| GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
| CZ20021484A3 (cs) * | 1999-10-27 | 2003-12-17 | Baker Norton Pharmaceuticals, Inc. | Farmaceutický prostředek obsahující taxan pro orální podávání lidem |
| US6638973B2 (en) * | 2000-02-02 | 2003-10-28 | Fsu Research Foundation, Inc. | Taxane formulations |
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| AU2001236009A1 (en) * | 2000-03-02 | 2001-09-12 | Hisamitsu Pharmaceutical Co. Inc. | P-glycoprotein modifier-containing medicinal compositions to be delivered to thelarge intestine |
| US6362217B2 (en) | 2000-03-17 | 2002-03-26 | Bristol-Myers Squibb Company | Taxane anticancer agents |
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| BR0213989A (pt) * | 2001-11-07 | 2005-03-01 | Pharmacia Corp | Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas |
| PL374283A1 (en) * | 2001-12-20 | 2005-10-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| JP2006514698A (ja) * | 2002-10-30 | 2006-05-11 | スフェリックス， インコーポレイテッド | ナノ粒子生物活性物質 |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| GB2423928B (en) * | 2004-11-16 | 2008-04-09 | Efflux Technology Inc | Methods and compositions for treating pain |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| CA2625700A1 (en) * | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
| CN101559059B (zh) * | 2008-04-16 | 2012-12-05 | 北京万全阳光医学技术有限公司 | 一种含有盐酸阿米洛利的药物组合物及其制备方法 |
| US20090318561A1 (en) * | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
| JP2011530532A (ja) * | 2008-08-07 | 2011-12-22 | シェーリング コーポレイション | 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物 |
| US7820681B1 (en) | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
| US20110046228A1 (en) * | 2009-08-20 | 2011-02-24 | Mutual Pharmaceutical Company, Inc. | Methods for administration of colchicine with grapefruit juice |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| US20120295932A1 (en) * | 2011-05-17 | 2012-11-22 | Western Connecticut Health Network, Inc. | Method for the treatment of cancer |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| TWI838700B (zh) | 2015-09-30 | 2024-04-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| CN107843966B (zh) | 2016-09-18 | 2021-05-04 | 中芯国际集成电路制造(上海)有限公司 | 用于装配微透镜阵列组件的方法和系统 |
| CN106822085B (zh) * | 2016-12-17 | 2020-03-17 | 浙江省人民医院 | 表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途 |
| US20230149377A1 (en) * | 2018-11-21 | 2023-05-18 | Elevar Therapeutics, Inc. | Pharmaceutical methods |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118493A (en) | 1986-05-02 | 1992-06-02 | Brigham And Women's Hospital | Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine |
| ES2059558T3 (es) | 1987-06-17 | 1994-11-16 | Sandoz Ag | Ciclosporins y su uso como productos farmaceuticos. |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤 |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
| US5208238A (en) | 1989-06-19 | 1993-05-04 | Burroughs Wellcome Company | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| GB8914040D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914061D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914060D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914062D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8926715D0 (en) | 1989-11-28 | 1990-01-17 | Haessle Ab | Improvements relating to the administration of pharmaceutical agents |
| JPH06504772A (ja) | 1990-12-18 | 1994-06-02 | ザ ウエルカム ファウンデーション リミテッド | 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤 |
| HUT68856A (en) | 1991-01-11 | 1995-08-28 | Glaxo Lab Sa | Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| CA2149150C (en) | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| CA2129288C (en) * | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| FR2718963B1 (fr) | 1994-04-25 | 1996-05-24 | Rhone Poulenc Rorer Sa | Nouvelle composition pharmaceutique à base de taxoïdes. |
| US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| GB9514878D0 (en) * | 1995-07-20 | 1995-09-20 | Danbiosyst Uk | Vitamin E as a solubilizer for drugs contained in lipid vehicles |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| CA2221444A1 (en) | 1996-01-31 | 1997-08-07 | Steven B. Hansel | A method of making pharmaceutically active taxanes orally bioavailable |
| US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
| US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
-
1996
- 1996-10-16 US US08/733,142 patent/US6245805B1/en not_active Expired - Fee Related
- 1996-10-24 DE DE0794794T patent/DE794794T1/de active Pending
- 1996-10-24 JP JP51644997A patent/JP3361102B2/ja not_active Expired - Fee Related
- 1996-10-24 DK DK96943268T patent/DK0794794T3/da active
- 1996-10-24 CN CN96191685A patent/CN1119146C/zh not_active Expired - Fee Related
- 1996-10-24 EP EP96943268A patent/EP0794794B1/en not_active Expired - Lifetime
- 1996-10-24 AU AU12056/97A patent/AU698142B2/en not_active Ceased
- 1996-10-24 ES ES96943268T patent/ES2109899T3/es not_active Expired - Lifetime
- 1996-10-24 IL IL12116096A patent/IL121160A0/xx unknown
- 1996-10-24 SK SK859-97A patent/SK85997A3/sk unknown
- 1996-10-24 CN CNB031458033A patent/CN100335123C/zh not_active Expired - Fee Related
- 1996-10-24 CA CA002205534A patent/CA2205534A1/en not_active Abandoned
- 1996-10-24 WO PCT/IB1996/001485 patent/WO1997015269A2/en active IP Right Grant
- 1996-10-24 AT AT96943268T patent/ATE311903T1/de not_active IP Right Cessation
- 1996-10-24 MX MX9704629A patent/MX9704629A/es not_active IP Right Cessation
- 1996-10-24 RU RU97112888/14A patent/RU2217135C2/ru not_active IP Right Cessation
- 1996-10-24 HU HU9900457A patent/HUP9900457A3/hu unknown
- 1996-10-24 CZ CZ972028A patent/CZ202897A3/cs unknown
- 1996-10-24 DE DE69636531T patent/DE69636531T2/de not_active Expired - Fee Related
- 1996-10-24 BR BR9607066-8A patent/BR9607066A/pt not_active Application Discontinuation
- 1996-10-24 PL PL96321791A patent/PL188281B1/pl not_active IP Right Cessation
- 1996-10-24 NZ NZ324801A patent/NZ324801A/xx unknown
- 1996-10-24 PL PL368566A patent/PL192544B1/pl unknown
-
1997
- 1997-06-25 NO NO19972968A patent/NO321091B1/no unknown
-
1998
- 1998-02-11 HK HK98101042A patent/HK1001960A1/xx not_active IP Right Cessation
-
2001
- 2001-04-10 US US09/829,846 patent/US6610735B2/en not_active Expired - Fee Related
-
2002
- 2002-09-12 US US10/242,050 patent/US6818615B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/800,990 patent/US7041640B2/en not_active Expired - Fee Related
-
2005
- 2005-04-13 US US11/105,081 patent/US20050238634A1/en not_active Abandoned
-
2006
- 2006-08-14 US US11/503,607 patent/US20070060635A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9900457A2 (hu) | Eljárás, készítmények és kellékkészlet gyógyszerhatóanyagok orális biológiai hasznosulásának a növelésére | |
| JP5613053B2 (ja) | 耳鳴を処置するための間欠療法 | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| BR9611802A (pt) | Composições farmacêuticas | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| BR9913696A (pt) | Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial | |
| GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
| HUP0302319A2 (hu) | Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására | |
| KR970706794A (ko) | 치핵 치료용 조성물 및 이의 사용방법(Hemorrhoidal compositions and method of use) | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| JP2009508869A (ja) | シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理 | |
| HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| HUP0400386A2 (hu) | Cetirizint és pszeudoefedrint tartalmazó tabletta és alkalmazása gyógyszerkészítmények előállítására | |
| BR0212155A (pt) | Composição farmacêutica | |
| Shinotoh et al. | Lamotrigine trial in idiopathic parkinsonism: a double‐blind, placebo‐controlled, crossover study | |
| JPH10505087A (ja) | 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物 | |
| WO2003089007B1 (en) | Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu | |
| HN2001000038A (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
| BRPI0415322A (pt) | composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina | |
| ITMI20121317A1 (it) | Composizioni per il trattamento della fatica oncologica | |
| EP2315586A1 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders | |
| JP2013049729A (ja) | 医薬組成物 | |
| JP3987501B2 (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): BARANYI EVA, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: SZENTPETERI ZSOLT SZABADALMI UEGYVIVOE, S.B.G., HU |
|
| FH92 | Termination of representative |
Representative=s name: BARANYI EVA, DANUBIA SZABADALMI ES VEDJEGY IRO, HU |
|
| HC9A | Change of name, address |
Owner name: IVAX RESEARCH, INC., US Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US; IVAX LABORATORIES, INC., US |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |